Erica Barnell, MD, PhD

GI Oncology Now

Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc, talks about the recent inclusion of ColoSense, a multitarget stool RNA test, in the National Comprehensive Cancer Network (NCCN) Guidelines for colorectal cancer screening.
Dr. Barnell highlights how the inclusion of this technology reduces disparities in colorectal cancer screening, how clinicians can integrate ColoSense in their clinic, and more.

Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc, talks about the recent inclusion of ColoSense, a multitarget stool RNA test, in the National Comprehensive Cancer Network (NCCN) Guidelines for colorectal cancer screening.Dr. Barnell highlights how the inclusion of this technology reduces disparities in colorectal cancer screening, how clinicians can integrate ColoSense in their clinic, and more.

Arvind Dasari, MD, MS

INTERCEPT-TT Trial: Exploring TAS-102 in CRC Patients With ctDNA-Defined Minimal Residual Disease After Adjuvant Therapy

Colorectal Cancer

Maen Abdelrahim, MD, PhD

Early Detection, Better Decisions: ctDNA as a Tool for Curative HCC Management

Liver Cancer

Emily Menendez

Radiotherapy With Sintilimab, Capecitabine, Oxaliplatin Effective as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Latest News

ColoSense Included in NCCN Guidelines for Colorectal Cancer Screening

Dr. Barnell discusses ColoSense's NCCN Guidelines inclusion for CRC and how it impacts the cancer screening landscape. 

ColoSense Included in NCCN Guidelines for CRC Screening

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable